Market research
QLGN Qualigen Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- 1.13
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.28
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74754R1032
- Market cap
- 7M
- P/E ratio
- 1.13
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.28
About
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the QLGN discussion.
5 years, 4 months ago
Qualigen Therapeutics, Inc is currently in a long term downtrend where the price is trading 37.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Qualigen Therapeutics, Inc's total revenue sank by 30.3% to $838K since the same quarter in the previous year.
Its net income has dropped by 1723.6% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 107.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Qualigen Therapeutics, Inc gets an overall score of 1/5.